Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic Screening Lung Adenocarcinoma Specific Migrasome Proteins

ABSTRACT: This study aims to investigate the potential application of migrasome proteins in the diagnosis of lung adenocarcinoma (LUAD) through proteomic analysis. Initially, migrasomes were extracted from plasma samples collected from 10 healthy individuals and 16 early-stage patients diagnosed with LUAD. Subsequently, label-free quantitative proteomics was employed to analyze the protein composition of the migrasomes derived from both cohorts. This comprehensive approach seeks to identify distinctive protein signatures that may serve as biomarkers for the early detection and diagnosis of lung adenocarcinoma.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma, Extracellular Vesicle

DISEASE(S): Lung Adenocarcinoma

SUBMITTER: Yixin Xu

LAB HEAD: Yixin Xu

PROVIDER: PXD074511 | Pride | 2026-04-27

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	FE221LQB1_D1.raw	Raw
	FE221LQB1_D10.raw	Raw
	FE221LQB1_D11.raw	Raw
	FE221LQB1_D12.raw	Raw
	FE221LQB1_D13.raw	Raw

Items per page:

1 - 5 of 28

Publications

Magnetic-Assisted Aptamer Selection and Isolation of Migrasomes for Application in Lung Adenocarcinoma Proteomic Analysis.

Xu Yixin Y Jiao Lin L Yi Qiangying Q Chen Yuzuo Y Cai Bei B Zhang Junlong J Huang Zhuochun Z Luo Yao Y Si Yanjun Y Wu Yao Y Ying Binwu B Chen Jie J Zhou Juan J

Journal of extracellular vesicles 20260401 4

Migrasomes, newly discovered vesicular organelles, hold promise as diagnostic biomarkers and therapeutic targets in various diseases. However, the exploration of their clinical value remains hindered by the complexity of enriching and analyzing low concentrations of migrasomes in body fluids. To address this issue, a magnetic-assisted strategy was devised for screening aptamers specific to migrasomes, with the identified aptamer then being utilized for the specific isolation of migrasomes derive ...[more]

PMID: 41995347

Similar Datasets

Proteomic Analysis of the Protein Composition of Migrasomes Enriched by Magnetic Aptamer Probe System and Density Gradient Centrifugation

Project description:This study aims to evaluate the performance of the magnetic aptamer probe (MAP) system in the enrichment of migrasomes. First, the MAP system was constructed by functionalizing biotin-labeled migrasome-targeting aptamers (Apt_B3) onto the surface of NeutrAvidin-coated magnetic sub-micrometre particles. To gain a deeper understanding of the system’s efficacy, we collected 4 clinical plasma samples and isolated the migrasomes using both traditional density gradient centrifugation (DGC) and the MAP system respectively. Subsequently, the protein composition of the migrasomes isolated by these two methods was analyzed using quantitative proteomics. To directly evaluate the reproducibility of our MAP isolation protocol, we compared the proteomic profiles of migrasomes isolated in two independent preparation batches. Batch-1 consisted of two replicates (MAP_a and MAP_b), and Batch-2 comprised four replicates (MAP_1-4). This approach seeks to demonstrate the promising applicability of the MAP system in studies related to clinical disease diagnosis of migrasomes.

2026-04-27 | PXD074521 | Pride

Integrative Multianalytical Model Based on Novel Plasma Protein Biomarkers for Distinguishing Lung Adenocarcinoma and Benign Pulmonary Nodules

Project description:Given the pressing clinical problem of making decision in diagnosis for subjects with pulmonary nodules, we aimed to discover novel plasma protein biomarkers for lung adenocarcinoma (LUAD) and benign pulmonary nodules (BPN), then develop an integrative multianalytical model to guide the clinical management of LUAD and BPN patients. Through label-free quantitative plasma proteomic analysis, twelve differentially expressed proteins (DEPs) in LUAD and BPN were screened. The diagnostic abilities of the DEPs were validated in two independent validation cohorts. The results showed that the level of three candidate proteins (PRDX2, PON1, APOC3) were lower in the plasma of LUAD than BPN. The three candidate proteins were combined with three promising computed tomography (CT) indicators (Spiculation, Vascular Notch Sign, Lobulation) and three traditional markers (CEA, CA125, CYFRA21-1) to construct an integrative multianalytical model, which was effective in distinguishing LUAD from BPN, with AUC of 0.904, sensitivity of 81.44% and specificity of 90.14%. Moreover, the model possessed impressive diagnostic performance between early LUADs and BPNs, with the AUC, sensitivity, specificity and accuracy of 0.868, 65.63%, 90.14% and 82.52%, respectively. This model maybe a useful auxiliary diagnostic tool for LUAD and BPN by achieving a better balance of sensitivity and specificity.

2024-01-26 | PXD046731 | Pride

A novel lncRNA, LUADT1 promotes lung adenocarcinoma proliferation by epigenetic suppression of p27

Project description:Long noncoding RNAs (lncRNAs) are known to regulate the development and progression of various cancers, however, few lncRNAs have been well characterized in lung adenocarcinoma (LUAD). Understanding the expression profile of lncRNAs and protein-coding genes is critical to develop new diagnosis and treatment strategies for LUAD and improving the prognosis of diagnosed patients. Five female LUAD patients with no smoking history were selected to profile lncRNA and protein-coding gene expression with microarrays. Paired tumor tissues and adjacent nontumor tissues were collected and confirmed by pathologists.

2015-03-10 | E-GEOD-66654 | biostudies-arrayexpress

Proteomic changes between primary tumors and matched distant metastases of lung adenocarcinomas

Project description:Lung cancer is the leading cause of cancer-related deaths worldwide and lung adenocarcinoma is the most common form of lung cancer. Genomic studies of lung adenocarcinoma (LUAD) have advanced our understanding of the disease's biology and accelerated targeted therapy. However, the proteomic characteristics of LUAD are still insufficiently understood. Prognosis for lung cancer patients remains poor and is strongly related to the stage of disease at the time of diagnosis. Therefore, our study focuses on metastasis formation in LUAD. We performed high-performance liquid chromatography (HPLC) and electrospray ionization tandem mass spectrometry (ESI-MS/MS) on a total of 40 FFPE samples and compared proteomic profiles of primary tumors to those of matched distant metastases. Using differential expression analysis and unsupervised clustering we identified candidate proteins playing a role in metastatic spread. Selected proteins were validated by immunoblotting. Our findings give a better understanding of tumor progression and metastasis formation in LUAD and might help to develop biomarker specific therapy.

2023-11-28 | PXD042604 | Pride

LC-MS of migrasomes and vesicles form human ccRCC 786-O cells

Project description:On one hand, we performed label-free quantitative proteomics to analyze migrasome proteins derived from 786-O cells vs ITM2B-knockdown 786-O cells.On the other hands,we isolated ITM2B truncation-containing vesicles and performed mass proteomic analysis to identify proteins that were carried by ITM2B truncation-containing vesicles. Through joint analysis of decreased proteins in ITM2B-knockdown migrasomes and proteins in vesicles, we discovered overlapping proteins, suggesting these proteins might be selectively sorted into migrasomes via ITM2B truncation-containing vesicles.

2025-10-06 | PXD054746 | Pride

Arraystar Human m6A-mRNA & lncRNA Epitranscriptomic microarray analysis in lung adenocarcinoma patient's tissues and adjacent non-tumor tissues

Project description:Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer and shows high morbidity and mortality rates as well as poor prognosis. However, there is still an urgent need to provide more effective biomarkers for the early diagnosis, prognosis and monitoring of LUAD. The Arraystar Human M6a-MRNA&lncRNA Epitranscriptomic microarray analysis was performed on six pairs of LUAD tissues and adjacent non-tumor tissues to compare and screen the M6a marker of LUAD, thus may offer a new avenue of targets and strategies for LUAD diagnosis and treatment.

2021-07-20 | GSE176348 | GEO

Glycoproteomics revealed novel N-glycosylation biomarkers for early diagnosis of lung adenocarcinoma cancers

Project description:Circulating biomarkers play important roles in diagnosis of malignant tumors. N-glycosylation is an important post-translation patter and obviously affect biological behaviors of malignant tumor cells. However, the role of N-glycosylation sites in early diagnosis of tumors still remains further investigation. In this study, plasma from 20 lung adenocarcinoma (LUAD), which were all classified as stage I, as well as 20 normal controls (NL) were labeled and screened by mass spectrometry (MS). Total 39 differential N-glycosylation sites were detected in LUAD, 17 were up-regulated and 22 were down-regulated. In all differential sites, ITGB3-680 showed highest potential in LUAD which showed 99.2% AUC, 95.0% SP and 95.0% SN. Besides, APOB-1523 (AUC: 89.0%, SP: 95.0%, SN: 70.0%), APOB-2982 (AUC: 86.8%, SP: 95.0%, SN: 45.0%) and LPAL2-101 (AUC: 81.1%, SP: 95.0%, SN: 47.4%) also acted as candidate biomarkers in LUAD. Combination analysis was then performed by random forest model, all samples were divided into training group (16 cases) and testing group (4 cases) and conducted by feature selection, machine learning, integrated model of classifier and model evaluation. And the results indicated that combination of differential sites could reach 100% AUC in both training and testing group. Taken together, our study revealed multiple N-glycosylation sites which could be applied as candidate biomarkers for early diagnosis diagnosis of LUAD.

2023-03-11 | PXD036198 | Pride

Hexokinase 2 detects cytokeratin negative circulating tumor cells in lung adenocarcinoma

Project description:Circulating tumor cells (CTCs) represent the molecular characteristics of tumor sites and travel in the blood for seeding distant metastases. "EpCAM+/pan-cytokeratin (CK)+/CD45-/DAPI+" has been widely accepted as a CTC definition, especially in breast cancer, prostate cancer and colorectal cancer. However, reports on CTC detection in non-small cell lung cancer are limited due to a lack of efficient CTC marker. We describe hexokinase 2 (HK2) that assays elevated glycolysis of cancer cells, called Warburg effect, as a new marker for CTC detection in lung adenocarcinoma (LUAD), especially the CK negative CTCs. Single-cell sequencing was used to confirm the malignancy of putative CTCs by detecting genome-wide copy number alternations characteristic of malignant cells. We employed this marker in a variety of liquid biopsies from LUAD patients, including peripheral blood, pleural effusion and cerebrospinal fluid.

2021-02-28 | E-MTAB-8767 | biostudies-arrayexpress

Super-SILAC-based quantitative proteomic analysis of lung adenocarcinoma associated with stage and EGFR gene status

Project description:Lung adenocarcinoma (LUAD) is one of the most common causes of cancer death worldwide. Epidermal growth factor receptor (EGFR) mutations (MT) frequently target LUAD patients in Eastern Asia. EGFR tyrosine kinase inhibitors were developed to benefit LUAD patients harboring EGFR-activating MT. Unfortunately, biomarkers for early diagnosis and targeted therapy for patients with wild-type (WT) EGFR are currently lacking. Based on the super-SILAC, this study established a LUAD proteomics data set related to stage and EGFR status. Specifically, proteins obtained from three locally established LUAD cell lines were pooled with LUAD tissues from women, never smokers, different histological stages (early and late), and EGFR status (wild-type and mutant) to establish a quantitative proteome data set. We integrated genomic datasets and proteomic resources to select marker candidates for further characterization via immunohistochemistry and ELISA assays. The biological significance of marker candidates was examined using cell lines. This study provides new insights into the diagnosis and tumorigenesis of LUAD with EGFR-WT.

2025-06-05 | PXD046807 | Pride

A novel lncRNA, LUADT1 promotes lung adenocarcinoma proliferation by epigenetic suppression of p27

2015-03-10 | GSE66654 | GEO